This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Guided Biopsy for Mapping Prostate Cancer (HIT)

This study has been terminated.
(Not able to meet accrual)
Information provided by (Responsible Party):
Roswell Park Cancer Institute Identifier:
First received: October 29, 2009
Last updated: February 26, 2014
Last verified: February 2014
Evaluate the accuracy of HIT guided biopsies for mapping tumor foci with men undergoing prostatectomy.

Condition Intervention
Prostate Cancer Procedure: Prostatectomy

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Hybrid Imaging Technique (HIT) Guided Biopsy to Map Prostatic Adenocarcinoma in Patients Undergoing Prostatectomy

Resource links provided by NLM:

Further study details as provided by Roswell Park Cancer Institute:

Primary Outcome Measures:
  • Determine the accuracy of hybrid image technology (HIT) guided biopsies for prostate cancer mapping. [ Time Frame: Six years ]

Enrollment: 7
Study Start Date: May 2010
Study Completion Date: February 2014
Primary Completion Date: February 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Prostate cancer
A total of 30 patients diagnosed with prostate cancer who have elected to undergo radical prostatectomy are enrolled over a six year period.
Procedure: Prostatectomy
Elective prostatectomy
Other Name: Prostate cancer

Detailed Description:
The objective of this study is to determine the accuracy of HIT (Hybrid Imaging Technology) guided biopsies for mapping tumor foci with men undergoing prostatectomy. Using a prostate hybrid imaging technology (HIT) which fuses a previously obtained endorectal MR image to transrectal ultrasound (TRUS) image to allow identification and biopsy of tumors by MR imaging in real time. We hypothesis that HIT guided biopsies will accurately localize the foci of prostate cancer.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must have histologically confirmed diagnosis of prostate cancer
  • Patients must have elected to undergo radical prostatectomy using an open, laparoscopic or robotic approach
  • Patients must be at least 18 years of age and able to provide written informed consent.
  • No history of radiotherapy, chemotherapy or hormone therapy within 6 months of surgery
  • Primary tumor must be amenable to surgical removal for curative intent
  • Patients must have ECOG-performance status 0 or 1 (appendix II)
  • Patients must have no history of rectal or anal disease.
  • Patients must have adequate organ function as defined by the following criteria:

    • Serum aspartate transaminase (AST; serum glutamic oxaloacetic transaminase [SGOT]) and serum alanine transaminase (ALT; serum glutamic pyruvic transaminase [SGPT])≤2.5x local laboratory upper limit of normal (ULN), or AST and ALT ≤5x ULN if liver function abnormalities are due to underlying malignancy
    • Total serum bilirubin ≤1.5 x ULN
    • Absolute neutrophil count(ANC)≥1,500/microL
    • Platelets≥lOO,OOO/microL
    • Hemoglobin≥9.0 g/dL
    • Serum calcium≤10.2mg/dL (correct for low albumin if necessary; calcium + (normal albumin - serum albumin)x 0.8)
    • Patients must have serum creatinine<2 mg/dL or serum creatinine clearance (CrCl)>40ml/min(CrCl= Wt(kg)x(140-age)*/72xCr. level,*female x 0.85)

Inclusion of minorities:

  • Members of all races and ethnic groups are eligible for this trial. Women and children are not eligible since prostate cancer is not diagnosed in these groups.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01007214

United States, New York
Roswell Park Cancer Institute
Buffalo, New York, United States, 14141
Sponsors and Collaborators
Roswell Park Cancer Institute
Principal Investigator: Anurag K Singh, MD Roswell Park
  More Information

Responsible Party: Roswell Park Cancer Institute Identifier: NCT01007214     History of Changes
Other Study ID Numbers: I 133608
Study First Received: October 29, 2009
Last Updated: February 26, 2014

Keywords provided by Roswell Park Cancer Institute:
Prostate cancer

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases processed this record on August 18, 2017